{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Duration of Response defined as the time, in months, from the date of first documentation of response to the date of disease progression. Response was assessed according to the IMWG classification response criteria.","groups":[{"description":"Plitidepsin was to be administered as a 3-hour (h) intravenous (i.v.) infusion at a dose of 5 mg/m2, on Day (D) 1 and 15, every four weeks (q4wk); BTZ was to be administered as a subcutaneous (s.c.) injection at a dose of 1.3 mg/m2 on D1, 4, 8 and 11, q4wk and DXM was to be taken orally at a dose of 40 mg/day on D1, 8, 15 and 22, q4wk. A cycle was defined as 28 days, plus any additional days required for dosing delays due to any reason. Treatment cycles were repeated q4wk.","id":"OG000","title":"Experimental"}],"paramType":"NUMBER","populationDescription":"Only one patient achieved a partial response","reportingStatus":"POSTED","timeFrame":"From the date of first documentation of response to the date of disease progression, up to 100 weeks","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}